Monitoring	O
the	O
efficiency	O
of	O
interferon	O
-	O
alpha	O
therapy	O
in	O
chronic	B-Cancer
myelogenous	I-Cancer
leukemia	I-Cancer
(	O
CML	B-Cancer
)	O
patients	O
by	O
competitive	O
polymerase	O
chain	O
reaction	O
.	O

Interferon	O
alpha	O
(	O
IFN	O
-	O
alpha	O
)	O
induces	O
cytogenetic	O
responses	O
of	O
variable	O
degree	O
in	O
patients	O
with	O
CML	B-Cancer
.	O

We	O
sought	O
to	O
establish	O
the	O
relationship	O
between	O
BCR	O
-	O
ABL	O
transcript	O
numbers	O
measured	O
by	O
competitive	O
two	O
-	O
step	O
reverse	O
transcription	O
polymerase	O
chain	O
reaction	O
(	O
RT	O
-	O
PCR	O
)	O
and	O
cytogenetic	O
status	O
in	O
CML	B-Cancer
patients	O
treated	O
with	O
IFN	O
-	O
alpha	O
.	O

All	O
398	O
samples	B-Cancer
from	O
163	O
patients	O
investigated	O
by	O
RT	O
-	O
PCR	O
were	O
positive	O
for	O
BCR	O
-	O
ABL	O
transcripts	O
.	O

In	O
order	O
to	O
standardize	O
results	O
for	O
variability	O
in	O
RNA	O
and	O
cDNA	O
quality	O
,	O
we	O
quantified	O
total	O
ABL	O
transcripts	O
in	O
each	O
sample	B-Cancer
as	O
internal	O
control	O
.	O

The	O
BCR	O
-	O
ABL	O
/	O
ABL	O
ratios	O
correlated	O
with	O
the	O
cytogenetic	O
results	O
.	O

Quantitative	O
nested	O
PCR	O
allowed	O
the	O
detection	O
of	O
residual	O
BCR	O
-	O
ABL	O
transcripts	O
in	O
all	O
complete	O
cytogenetic	O
responders	O
on	O
IFN	O
-	O
alpha	O
.	O

We	O
conclude	O
that	O
competitive	O
PCR	O
with	O
internal	O
controls	O
is	O
a	O
reliable	O
method	O
for	O
monitoring	O
patients	O
on	O
IFN	O
-	O
alpha	O
and	O
reduces	O
the	O
need	O
for	O
repeated	O
marrow	B-Multi-tissue_structure
investigations	O
.	O

